Answer

Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence

Retrieved on: 
星期二, 五月 28, 2024

11

Key Points: 
    • 11

      Reflection paper on use of real-world data in noninterventional studies to generate real-world evidence

      12

      Table of contents

      13

      1.

    • References ............................................................................................ 15

      10

      Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 2/16

      44

      1.

    • Introduction

      45

      This reflection paper discusses methodological aspects of non-interventional studies (NIS) using real-

      46

      world data (RWD) in order to generate real-world evidence (RWE) for regulatory purposes.

    • These include absence of randomisation, uncontrolled conditions, non-

      61

      standardised treatments and uncertainties regarding data quality and completeness.

    • The

      63

      increasing ability to capture electronic healthcare data and data from registries is now providing new

      64

      opportunities to use RWD and generate RWE that reflects clinical practice.

    • Scope

      89

      The scope of this reflection paper is the design, conduct and analysis of NIS using RWD to generate

      90

      RWE for regulatory purposes.

    • data collected specifically for the study in

      106

      question, or secondary use of existing data sources.

    • In both cases, attention should be paid to the

      107

      possible selection mechanisms in the data collection, for example the inclusion of specific patients or

      108

      the collection of specific clinical data.

    • Reference to studies with causal objectives in this document does not

      119

      imply an expectation that specific analytical methods will be used.

    • Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 4/16

      128

      The legal obligations and regulatory requirements applicable to NIS should be followed.

    • 138

      ?

      Regulation (EU) 2016/679 on the protection of natural persons with regard to the processing of

      139
      140

      personal data and on the free movement of such data.

    • The specific aim of the study forms the basis for the

      164

      selection of data source(s), study design, and analysis approach.

    • Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 5/16

      166

      4.2.

    • Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 6/16

      208

      ?

      Regional differences in clinical practice and healthcare systems management, e.g.

    • Misclassification can arise at many different

      296

      steps of data collection and extraction: diagnosis, coding, recording, data transformation, data

      297

      aggregation, summarisation, and analysis.

    • Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 12/16

      452

      6.4.

    • For these studies, the study protocol should describe:

      456

      ?

      The data elements used to link the data.

    • Heterogeneity

      530

      In multi-database studies, different estimates may be found even when the same protocol is applied

      531

      across all data sources (22).

    • (2023)
      Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 15/16

      569
      570

      15.

    • Draft guidance Real-World Data: Assessing Electronic Health Records and Medical Claims
      Data To Support Regulatory Decision-Making for Drug and Biological Products (2021)

      571
      572
      573

      16.

    • Reflection paper on use of real-world data in non-interventional studies to generate
      real-world evidence
      EMA/CHMP/150527/2024

      Page 16/16

FDA Roundup: April 26, 2024

Retrieved on: 
星期五, 四月 26, 2024

On Thursday, the FDA announced it has approved the first generic pimobendan for the management of congestive heart failure in dogs.

Key Points: 
  • On Thursday, the FDA announced it has approved the first generic pimobendan for the management of congestive heart failure in dogs.
  • The FDA expects this firm to fully address the violations described in the warning letter.
  • This represents the first FDA approval of a radioactive drug, or radiopharmaceutical, for pediatric patients 12 years of age and older with SSTR-positive GEP-NETs.
  • This represents the first FDA approval of a systemic therapy for the treatment of patients with pediatric LGG with BRAF rearrangements, including fusions.

ILUS Provides Form 10-K Filing Update

Retrieved on: 
星期三, 四月 17, 2024

These statements are not guarantees of future performance and undue reliance should not be placed on them.

Key Points: 
  • These statements are not guarantees of future performance and undue reliance should not be placed on them.
  • The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.
  • The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material non-public information.
  • It is possible that the information we post on social media could be deemed to be material information.

ISACA's CISA Exam Updated to Reflect Innovations and Evolving Technologies Impacting IT Audit

Retrieved on: 
星期三, 五月 1, 2024

ISACA’s Certified Information Systems Auditor® (CISA®) certification is being updated to reflect the most current industry trends impacting the IT audit profession.

Key Points: 
  • ISACA’s Certified Information Systems Auditor® (CISA®) certification is being updated to reflect the most current industry trends impacting the IT audit profession.
  • The job practice update considers innovations and evolving technologies related to the current role of an IT audit professional.
  • The updated exam will be available on 1 August 2024 and the new CISA exam preparation materials will be available starting 1 May 2024.
  • However, the updated exam content outline requires testing of risk, security, and controls related to disruptive technologies and emerging IT audit practices.

“Happy Women” Podcast with Jennifer Horn and Katie Gorka Launches on the Salem Podcast Network

Retrieved on: 
星期一, 四月 22, 2024

Salem Media Group , Inc. (OTCQX: SALM) announced today that the "Happy Women” podcast, hosted by Jennifer Horn and Katie Gorka will launch on the Salem Podcast Network on Tuesday, April 23rd, with two episodes released each week.

Key Points: 
  • Salem Media Group , Inc. (OTCQX: SALM) announced today that the "Happy Women” podcast, hosted by Jennifer Horn and Katie Gorka will launch on the Salem Podcast Network on Tuesday, April 23rd, with two episodes released each week.
  • View the full release here: https://www.businesswire.com/news/home/20240419872737/en/
    Katie Gorka and Jennifer Horn (Photo: Business Wire)
    “As we work hard to save America, we know women will be at the forefront.
  • I can’t wait to hear this podcast with two strong women who have great chemistry and rapport together,” said Salem Senior Vice President of Spoken Word, Phil Boyce.
  • "I am so excited to partner with Katie Gorka and the Salem Podcast Network on ‘Happy Women’”, said Jennifer Horn.

Convr AI® Celebrating Eight Years in InsurTech Business

Retrieved on: 
星期三, 四月 17, 2024

CHICAGO, April 17, 2024 /PRNewswire-PRWeb/ -- t's hard to believe, but Convr the leading artificial intelligence (AI) company serving commercial insurance organizations is already saying cheers to eight years of serving customers with its modularized underwriting workbench in 2024.

Key Points: 
  • The company founded by underwriters for underwriters and formerly called DataCubes is passionate about the commercial property and casualty insurance business.
  • "Convr continues to lead innovation in the AI commercial insurance underwriting space and this milestone showcases our dedication to unlocking even more performance improvements for customers in the coming years," said Convr CEO, John Stammen.
  • The company founded by underwriters for underwriters in 2016 and formerly called DataCubes is passionate about the commercial property and casualty (P&C) insurance business.
  • "Convr continues to lead innovation in the AI commercial insurance underwriting space and this milestone showcases our dedication to unlocking even more performance improvements for customers in the coming years," said Convr CEO, John Stammen.

CENTRL Announces First Of Its Kind AI-Powered DDQ Response Solution

Retrieved on: 
星期四, 四月 11, 2024

MOUNTAIN VIEW, Calif., April 11, 2024 /PRNewswire-PRWeb/ -- CENTRL, a leading innovator in AI-powered third-party risk and diligence solutions for the financial industry, today launches its groundbreaking generative AI solution tailored specifically for responders of Due Diligence Questionnaires (DDQs), security questionnaires, and more. Leveraging cutting-edge generative AI technology, Response360 is a first-to-market solution that dramatically reduces the time spent answering questionnaires while increasing the accuracy of responses.

Key Points: 
  • Leveraging cutting-edge generative AI technology, Response360 is a first-to-market solution that dramatically reduces the time spent answering questionnaires while increasing the accuracy of responses.
  • We have been testing the solution with response teams across Banks, Asset Managers and Service providers and the feedback has been incredibly positive" said Sanjeev Dheer, Founder and CEO.
  • We have been testing the solution with response teams across Banks, Asset Managers and Service providers and the feedback has been incredibly positive.
  • We look forward to partnering with clients to rapidly evolve the solution," said Sanjeev Dheer, Founder and CEO.

CGRA Announces Completion and Publication of 2023 Annual Disclosure

Retrieved on: 
星期四, 三月 28, 2024

These statements are not guarantees of future performance and undue reliance should not be placed on them.

Key Points: 
  • These statements are not guarantees of future performance and undue reliance should not be placed on them.
  • The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material non-public information.
  • We use these channels as well as social media to communicate with the public about our company, our services, and other issues.
  • It is possible that the information we post on social media could be deemed to be material information.

Organic's best honored at "An Organic Night Out"

Retrieved on: 
星期四, 三月 14, 2024

Hosted by The Organic Center and Organic Voices, “An Organic Night Out” showcased honorees in eight categories – all nominated and chosen by their peers.

Key Points: 
  • Hosted by The Organic Center and Organic Voices, “An Organic Night Out” showcased honorees in eight categories – all nominated and chosen by their peers.
  • “We’re honored to accept this award from The Organic Center and Organic Voices,” states Paul Lightfoot, General Manager of Patagonia Provisions.
  • It promotes their holiday offerings through an “Organic menu,” puts together organic cheese boards for its shoppers and helps them choose the best organic wines.
  • "The growth of organic doesn't happen in a vacuum; it takes the commitment and hard work of organic farmers, businesses and researchers to advance organic."

Questions and answers on the European Union framework for (traditional) herbal medicinal products, including those from a ‘non-European’ tradition

Retrieved on: 
星期日, 三月 10, 2024

1

Key Points: 
    • 1
      Committee on Herbal Medicinal Products (HMPC)

      Questions & Answers on the European Union framework
      for (traditional) herbal medicinal products, including those
      from a ?non-European? tradition

      Table of Content
      1.

    • European Pharmacopoeia

      SAWP

      Scientific Advice Working Party

      SmPC

      Summary of Product Characteristics

      THMP

      Traditional Herbal Medicinal Product

      TUR

      Traditional Use Registration

      WEU

      Well-Established Use

      Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

    • Terminology of herbal medicinal products (Q&A 1-4)

      Question 1
      What are herbal substances, herbal preparations, and herbal medicinal products?

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Question 4
      Are food supplements regulated under the European Union (EU) pharmaceutical legislation
      for (traditional) herbal medicinal products ((T)HMPs)?
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Regulation of herbal medicinal products in the European Union (Q&A 511)

      Question 5
      Where to find the pharmaceutical legislation and dossier requirements for herbal medicinal
      products (HMPs), including traditional herbal medicinal products (THMPs), in the European
      Union (EU)?

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • These countries have,
      through the EEA agreement, adopted the complete Union acquis on medicinal products and are
      consequently parties to the Union procedures.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Specific provisions for traditional herbal medicinal products (Q&A 1221)

      Question 12
      Which indications can be granted for traditional herbal medicinal products (THMPs)?

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Nov. 2023
      Answer 17

      Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Question 29
      Does the Committee on Herbal Medicinal Products (HMPC) hold a specific database on
      (registered) authorised (traditional) herbal medicinal products ((T)HMPs)?
    • Discussion with Member States intended to be

      Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.